Compass Pathways PLC (NASDAQ:CMPS) is among the best psychedelic stocks to buy in 2026. Its flagship psychedelic drug ...

The average one-year price target for COMPASS Pathways plc - Depositary Receipt (NasdaqGS:CMPS) has been revised to $23.77 / share. This is an increase of 19.77% from the prior estimate of $19.84 ...

COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically ...

Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 The ...

Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss. Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year.

Compass Pathways (NASDAQ:CMPS) executives outlined plans for a potential U.S. regulatory filing and commercial launch ...

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...

See what Compass Pathways’ Phase 3 COMP360 TRD data showed, why the stock jumped, and how a discounted offering reshapes the ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the ...